Offer An Article

Pandemic Latest News

Access to Healthcare

Intellectual Property Rights policy may hinder drug access

India’s National Intellectual Property Rights (IPR) policy, reported in the Hindu’s business pages earlier in May, could pose a “serious” hurdle to allowing access to affordable drugs, according to experts.The policy has left the country’s patent laws intact and specifically did not open up Section 3(d) of the Patents Act for reinterpretation, the clause which …

Intellectual Property Rights policy may hinder drug access Read More »

New threat against affordable medicines in trade negotiations with India and ASEAN

According to an article by Médecins Sans Frontières (MSF) last month, access to affordable medicines could be severely restricted for millions of people around the world under the current proposals in the Regional Comprehensive Economic Partnership (RCEP) trade agreement. MSF sounded the alarm regarding the potential harmful consequences of the trade deal ahead of the …

New threat against affordable medicines in trade negotiations with India and ASEAN Read More »

Lower prices or better infrastructure?

That’s the question the government must address say the OPPI. According to an article by the Organisation of Pharmaceutical Producers of India (OPPI), price control is neither a viable nor sustainable strategy for increasing access to medicines.  Director general of Organisation of Pharmaceutical Producers of India (OPPI), Ranjana Smetacek said “The focus must shift from …

Lower prices or better infrastructure? Read More »

Patents Don’t Affect The Prices Of Medicines As Much As We Think They Do

Debates on how to improve healthcare in developing countries often include this premise: patents can potentially raise drug prices, so they should be abolished for better public health. This point of view is particularly widely held in a country like India, with the government’s latest National  Sample Survey Office report pointing out 86 percent of …

Patents Don’t Affect The Prices Of Medicines As Much As We Think They Do Read More »

Patients mount challenge against Gilead’s patent on new Hep C drug

A day after US company Gilead was granted a patent on hepatitis C medicine, sofosbuvir, patient groups and companies are planning to challenge it. I-MAK and health advocates around the world agree that sofosbuvir does not deserve a patent, and will be launching an appeal to the decision. The order may block a sustainable supply …

Patients mount challenge against Gilead’s patent on new Hep C drug Read More »

Drug pricing regime needs to be predictable,transparent:Sanofi

Government must not place the entire burden of access to healthcare on the pharmaceutical industry alone, Sanofi India has said responding to more medicines being put under price control. Speaking at the company’s annual general meeting held on April 29, the Sanofi India Managing Director Shailesh Ayyangar said any pricing regime must be predictable and …

Drug pricing regime needs to be predictable,transparent:Sanofi Read More »

Price caps on drugs boost access to essential medicines

India’s poor will benefit from improved access to essential medicines in India after the government capped the prices of 530 drugs under the price monitoring mechanism, reports The Pharma Letter. Around 47 formulations for cancer, 20 for AIDS/HIV, 53 for cardiovascular diseases and six for diabetes have had their prices reduced recently. As a result …

Price caps on drugs boost access to essential medicines Read More »